Loading…
Maker of orthobiologics products, including bone-graft substitutes and hyaluronic-acid injections for joint pain and healing.
Maker of orthobiologics products, including bone-graft substitutes and hyaluronic-acid injections for joint pain and healing.
Sells mainly to orthopaedic and pain clinics, which buy injections such as hyaluronic acid (a lubricating gel put into the knee) and are paid back by insurers, so insurer coverage and surgeon preference matter as much as the clinical case. A bone-healing ultrasound device, Exogen, gives it a second, steadier line.
Moat: narrow (brand, regulatory licence). Established orthobiologics brands with regulatory approvals, though facing generic/biosimilar-style competition.
Headquarters: Durham, North Carolina · Founded: 2012 · Employees: 930
Size Bioventus (BVS) is a United States Health Care company (Medical Specialties) with a market value of $894M, the 2317th largest of 3,117 United States companies the cockpit tracks. Shares closed at $10.61 on 6 Nov 2026.
Performance Over six months the shares gained 1.1%, against -13.8% for the median peer and -1.1% for the United States market (cap-weighted) — 9th highest of 21 in its peer set.
Growth Revenue grew 3.9% over the last twelve months (peer median +12.3%); the operating margin is 10.1% (peer median 12.2%).
Valuation It trades at 13.1× forward earnings against a peer median of 23.5× (3rd cheapest of 18).
Price implies For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is -5 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 1.1 points above its cost of capital (7.6% WACC).
Short interest Short interest is 4.7% of the free float (15 Oct 2026).
Next results Next results expected around 11 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $586M | $568M | $573M | $512M | $512M |
| Revenue growth | — | -1% | +12% | 0% | — |
| Gross profit | $398M | $382M | $381M | $319M | $321M |
| EBITDA | $103M | $106M | $100M | $73.4M | $52.8M |
| Net income | $57.3M | $22.7M | -$36.1M | -$156M | -$159M |
| Free cash flow | $84.3M | $71.4M | $36.6M | $7.98M | -$23.6M |
| Capital expenditure | $2.45M | $2.56M | $1.72M | $7.36M | $11.5M |
| Total debt | $244M | $311M | $356M | $409M | $436M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Bioventus BVS | $894M | +1% | +4% | 10% | 13.1× | 6.9% |
| Zimmer Biomet ZBH | $20.1B | +29% | +7% | 16% | 12.0× | -1.4% |
| Stryker SYK | $124B | +14% | +8% | 25% | 20.4× | 10.6% |
| Organogenesis ORGO | n/a | -66% | n/a | n/a | n/a | n/a |
| Smith & Nephew SN..L | $13.1B | +5% | +2% | 17% | 14.4× | 11.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | BVS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -16.4% | -5.2% | 3rd lowest of 21 |
| 6-month return | +1.1% | -13.8% | 9th highest of 21 |
| Distance from 52-week high | -33.2% | -36.2% | 10th highest of 21 |
| Revenue growth (TTM) | +3.9% | +12.3% | 8th lowest of 21 |
| Operating margin | 10.1% | 12.2% | 9th lowest of 21 |
| Forward P/E | 13.1× | 23.5× | 3rd cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | 6.9% | 4.3% | 8th most demanding of 17 |
| Growth delivered (Del g) | +12.1% | +11.5% | 8th highest of 17 |
| Hurdle (Req g minus delivered) | -5.1 pp | -4.3 pp | 9th least demanding of 17 |
| ROIC minus cost of capital | +1.1 pp | +3.5 pp | 7th lowest of 21 |
| EV / EBITDA | 11.2× | 9.4× | 6th most expensive of 12 |
| Net debt / EBITDA | 2.1× | -0.4× | 2nd most indebted of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Bioventus BVS | United States | $894M | +1% | +4% | 10% | 13.1× | 6.9% | +12.1% |
| Safilo SFL.MI | Italy | $890M | +24% | -4% | 9% | 16.0× | -0.5% | +4.7% |
| Cisen Pharmaceutical 603367.SS | China | $890M | -15% | -6% | 8% | 8.3× | -12.9% | -1.3% |
| Mani 7730.T | Japan | $909M | -15% | +10% | 30% | 18.4× | 1.5% | +13.9% |
| Shanghai Runda Medical Technology 603108.SS | China | $909M | -25% | -12% | -2% | 25.1× | 22.2% | -0.2% |
| Beijing SDL Technology 002658.SZ | China | $910M | -21% | -13% | 9% | 23.6× | 18.0% | +2.9% |
| LifeTech Scientific 1302.HK | Hong Kong | $914M | -18% | +1% | 12% | 23.5× | 13.3% | +15.5% |
| Ningbo Jansen Superconducting Technologies 688805.SS | China | $915M | -30% | +36% | 14% | n/a | 47.2% | +17.1% |
| Seegene 096530.KS | South Korea | $915M | +26% | +12% | 13% | 15.9× | -3.4% | -15.9% |
| Modern Dental 3600.HK | Hong Kong | $871M | +19% | +12% | 22% | 8.8× | -7.0% | +11.3% |
| Aidite (Qinhuangdao) Technology 301580.SZ | China | $919M | -20% | +17% | 18% | 27.1× | 19.9% | +23.3% |
| Sino Medical Sciences Technology 688108.SS | China | $868M | -35% | +22% | 19% | 69.2× | 31.0% | +9.9% |
| JINS 3046.T | Japan | $865M | -12% | +14% | 10% | 16.6× | -7.2% | +11.7% |
| MedCap MCAP.ST | Sweden | $864M | +6% | +17% | 15% | 26.4× | 2.9% | +20.9% |
| Menicon 7780.T | Japan | $854M | +12% | +5% | 9% | 19.3× | n/a | n/a |
| Beta Bionics BBNX | United States | $854M | +63% | +44% | -73% | n/a | n/a | n/a |
| Caina Technology 301122.SZ | China | $938M | +60% | +61% | 0% | 72.0× | n/a | n/a |
| Zylox-Tonbridge Medical Technology 2190.HK | Hong Kong | $851M | -13% | +39% | 25% | 15.9× | 5.5% | +105.8% |
| Shantou Institute of Ultrasonic Instruments 301602.SZ | China | $944M | -19% | +4% | 30% | n/a | 13.1% | +4.6% |
| Shenzhen YHLO Biotech 688575.SS | China | $950M | -20% | +3% | 12% | 37.2× | 3.1% | +12.7% |
| Kuros Biosciences KURN.SW | Switzerland | $953M | +3% | +41% | 6% | 73.8× | n/a | n/a |